Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oogenesis02:07

Oogenesis

70.4K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
70.4K
Ovaries01:26

Ovaries

2.8K
The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of...
2.8K
Ovarian Cycle01:27

Ovarian Cycle

4.5K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does sonographic visual biofeedback before or during the second stage of labor improve outcomes? A meta-analysis.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same author

Linking Neonatal Birth Weight with AMH Levels in Umbilical Cord and Maternal Blood: A Prospective Study.

International journal of women's health·2026
Same author

Hormone Therapy After Oophorectomy and Breast Cancer Risk in Women With BRCA Pathogenic Variant.

JAMA network open·2026
Same author

Impact of concomitant hysterectomy on quality of life in BRCA carriers undergoing risk-reducing salpingo-oophorectomy.

Maturitas·2026
Same author

Is pharmacologic thromboprophylaxis needed in robotic-assisted hysterectomy? A big data study.

Journal of robotic surgery·2026
Same author

Efficacy of energy-based devices on episiotomy pain and healing: A systematic review and meta-analysis.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2025

Related Experiment Video

Updated: Feb 23, 2026

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.8K

[LOW GRADE OVARIAN CANCER].

Yakir Segev1, Anis Kaldawy1, Ron Auslender1

  • 1Department of Obstetrics and Gynecology, The Lady Davis Carmel Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Harefuah
|August 31, 2017
PubMed
Summary

Low grade serous cancer (LGSC) is distinct from high grade serous cancer (HGSC), often driven by MAPK pathway mutations. While presenting similarly to HGSC, LGSC may have a better prognosis despite lower chemotherapy sensitivity.

More Related Videos

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.3K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.5K

Related Experiment Videos

Last Updated: Feb 23, 2026

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.8K
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.3K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.5K

Area of Science:

  • Gynecologic Oncology
  • Molecular Pathology
  • Cancer Genomics

Background:

  • Low grade serous cancer (LGSC) is differentiated from high grade serous cancer (HGSC) by distinct pathological and molecular features.
  • LGSC exhibits a lower mitotic index and nuclear atypia compared to HGSC.
  • LGSC frequently displays mutations in the mitogen-activated protein kinase (MAPK) pathway, particularly KRAS and BRAF genes.

Purpose of the Study:

  • To elucidate the unique characteristics of LGSC in comparison to HGSC.
  • To explore the prognostic implications of MAPK pathway mutations in LGSC.
  • To review current and emerging treatment strategies for LGSC.

Main Methods:

  • Comparative analysis of pathological and molecular data between LGSC and HGSC.
  • Review of clinical presentation, staging, and treatment outcomes.
  • Investigation of potential precursor lesions, such as borderline tumors.

Main Results:

  • LGSC presents with symptoms and advanced stages similar to HGSC, but often has a better prognosis.
  • MAPK pathway mutations in LGSC may correlate with a more favorable outcome.
  • Lower proliferation rates in LGSC may contribute to reduced sensitivity to conventional chemotherapy.

Conclusions:

  • LGSC represents a distinct entity from HGSC, characterized by specific genetic alterations and prognostic factors.
  • Borderline tumors may precede the development of some LGSC cases, sharing common molecular pathways.
  • Targeted therapies focusing on the MAPK pathway show promise for LGSC treatment in ongoing clinical trials.